Targeting Inflammatory Cytokines in Autoimmune Diseases: Mechanisms and Therapeutic Advances with Antibody-Based Therapies

Autoimmune diseases occur due to dysregulated immune responses against self-antigens, marked by chronic inflammation caused by pathogenic cytokine networks. Key inflammatory mediators, such as TNF-α, IL-6, IL-17, IL-23, and type I/II interferons, promote disease progression by activating autoreactive lymphocytes, recruiting immune cells, and causing ongoing tissue damage. The development of therapeutic antibodies targeting these cytokines has transformed treatment approaches, providing targeted immunomodulation while reducing systemic immunosuppression. Clinically approved biologics, including TNF inhibitors (Adalimumab, Infliximab), IL-6R blockers (Tocilizumab), and IL-17/IL-23 pathway antagonists (Secukinumab, Ustekinumab), show strong efficacy in various autoimmune conditions like rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. Emerging strategies, such as bispecific antibodies and AI-optimized designs, further enhance therapeutic precision by targeting multiple inflammatory pathways or refining antibody functions simultaneously. This review highlights the pivotal role of inflammatory cytokines in autoimmune pathogenesis and assesses the clinical impact of cytokine-targeted biologics, emphasizing their potential for achieving disease modification and long-term remission. Future advancements in personalized immunomodulation are expected to improve therapeutic outcomes for refractory autoimmune diseases.